Transforming Disease Drivers into Health Value Drivers.
Turning routine retinal OCT Eye Scans data into actionable Population Health Intelligence!
About Ascento-CDA
The Challenge
Healthcare sees disease. Biology often reveals it earlier.
Chronic diseases frequently develop and progress long before symptoms, clinical deterioration, or conventional diagnostic thresholds become visible.
Population health organizations can identify patients with elevated long-term risk, but they still have limited visibility into which individuals are experiencing active biologic change and may benefit most from intervention today.
As a result, care is often initiated only after disease progression has become measurable, more difficult to reverse, and more costly to manage.
Healthcare needs a scalable way to detect the biologic activity driving deterioration earlier—and translate that insight into better patient prioritization and more timely care.
Better Population Health Starts with Better Biologic Intelligence
Biologic Intelligence is the ability to detect and interpret the biologic processes that drive disease progression before conventional clinical manifestations become apparent.
Ascento-CDA transforms routine retinal OCT data into actionable Population Health Intelligence by revealing underlying biologic disease drivers through advanced image-derived biomarkers. These insights help healthcare organizations identify patients who are actively progressing, prioritize those who will benefit most from early intervention, and support more informed clinical decision-making.
Built on existing OCT infrastructure and designed for value-based care, the Ascento Biologic Intelligence Platform enables healthcare providers to move beyond detecting disease toward understanding the biology that drives it.
From Disease Drivers to Health Value Drivers
Every chronic disease is driven by underlying biologic processes that begin long before irreversible damage or clinical symptoms appear. Persistent inflammation, immune dysregulation, microvascular dysfunction, accelerated biologic aging, and other molecular changes silently influence how disease develops and progresses.
We refer to these underlying biologic processes as Disease Drivers.
Understanding these drivers provides a fundamentally different view of patient health. Rather than focusing solely on the presence of disease, clinicians gain insight into the biologic activity that is actively shaping future outcomes.
Ascento-CDA transforms these biologic insights into Health Value Drivers—actionable intelligence that helps healthcare organizations identify who needs intervention, prioritize care management resources, personalize follow-up, and support better clinical and economic outcomes.
How it Works
IICM™ — detect earlier - remediate with precision.
The Inflammatory, Immunologic & Cognitive Mapping Platform (IICM™) integrates several accessible, clinically validated data streams — then uses AI to map the specific biological drivers promoting disease in each patient, giving clinicians the context to act, not just diagnose.
Routine OCT Scan
Millions of retinal OCT scans are performed every year as part of routine eye care. No additional imaging or change in clinical workflow is required.
Biologic Signal Extraction
Advanced image-derived biomarkers are extracted from the OCT data, revealing subtle structural patterns associated with underlying biologic activity.
Biologic Intelligence
The Ascento Biologic Intelligence Platform analyzes advanced image-derived biomarkers to identify Disease Drivers and assess the level of biologic activation associated with chronic disease progression.
Clinical Enrichment (when appropriate)
Depending on the clinical application, additional assessments—such as digital cognitive testing, blood biomarkers, or other clinical information—can be integrated to provide a more comprehensive understanding of patient status and support clinical decision-making.
Health Value Drivers
The integrated biologic insights are translated into actionable Health Value Drivers that help healthcare organizations identify patients who are actively progressing, prioritize interventions, and optimize care management.
Rather than asking whether disease is already present, Ascento asks a different question: What biologic processes are actively driving disease progression today?
Opportunity
Recent advances in retinal imaging, biologic analytics, and artificial intelligence now make it possible to identify biologic disease drivers before conventional clinical deterioration becomes apparent.
For clinicians, this means earlier, more informed diagnostic decisions and targeted remediation.
For insurers, a measurable path to reduced long-term costs.
WHAT'S NOW POSSIBLE — 1
Earlier detection to support confident diagnosis
By integrating OCT retinal imaging, cytokine biomarker analysis, and advanced cognitive testing, IICM™ surfaces biological signals years before they become clinically visible — giving doctors the data they need to identify at-risk patients and diagnose earlier and with greater certainty.
WHAT'S NOW POSSIBLE — 2
Root-cause intelligence for targeted remediation
Detection alone isn't enough. IICM™ maps the specific inflammatory and metabolic drivers promoting disease in each patient — giving clinicians the biological context to design interventions that address root cause, not just symptoms.
Indications
One Biologic Intelligence Platform. Multiple Clinical Indications.
The Ascento Biologic Intelligence Platform is designed to identify biologic disease drivers that contribute to the onset and progression of chronic disease. Because many chronic conditions share common inflammatory, vascular, immune, and metabolic pathways, the platform can be applied across multiple clinical indications while utilizing the same scalable OCT-based infrastructure.
Our initial clinical validation focused on cognitive decline, where the need for earlier biologic insight is particularly acute. This work established the scientific and clinical foundation for expanding the platform into additional chronic diseases that share common underlying biologic pathways.
Current areas of focus include:
- Cognitive Decline – Detecting biologic changes associated with increased risk of cognitive impairment and supporting earlier intervention.
- Diabetes Progression – Identifying patients with active biologic deterioration despite apparent clinical stability.
- Cardiovascular Disease – Revealing biologic patterns linked to vascular dysfunction and cardiovascular risk.
- Chronic Kidney Disease – Supporting earlier identification of patients with systemic biologic changes associated with renal deterioration.
- Biologic Aging – Assessing biologic activity associated with accelerated aging and loss of physiologic resilience.
- Inflammatory and Immune-Mediated Diseases – Characterizing underlying inflammatory and immune activation across chronic conditions.
As additional clinical evidence is generated, the platform will continue to expand into new indications where earlier biologic intelligence can improve patient stratification, clinical decision-making, and population health outcomes.
Creating Value Across Healthcare
For Accountable Care Organizations
- Identify patients with hidden biologic deterioration before costly complications occur
- Enable proactive intervention in clinically "stable" but silently deteriorating populations
- Support shared savings through reduced downstream utilization
- Improve chronic disease management and quality performance
- Prioritize high-risk patients for targeted care management
- Leverage existing OCT infrastructure for scalable population screening
For Health Providers
- Detect hidden biologic activity before clinical deterioration
- Enable more personalized intervention strategies
- Support evidence-informed treatment decisions through biologic validation
- Expand reimbursable clinical workflows
- Strengthen performance in value-based care programs
For Payers
- Earlier identification of avoidable deterioration
- Support proactive disease management
- Reduce downstream complication costs
- Improve quality performance
- Enable more effective allocation of preventive resources
- Create measurable ROI from early intervention programs